| ECRHS II | EGEA2 | p-value# | |
| Subjects n | 1895 | 641 | |
| Age yrs | <0.0001 | ||
| <40 | 760 (40.1) | 359 (56.0) | |
| ≥40 | 1135 (59.9) | 282 (44.0) | |
| Sex | <0.0001 | ||
| Males | 780 (41.2) | 337 (52.6) | |
| Females | 1115 (58.8) | 304 (47.4) | |
| Age at asthma onset yrs | <0.0001 | ||
| ≤4 | 289 (15.8) | 189 (31.4) | |
| 4–16 | 558 (30.5) | 210 (34.9) | |
| >16 | 982 (53.7) | 203 (33.7) | |
| Wheezing with breathlessness¶ | 0.16 | ||
| No | 871 (46.4) | 312 (48.9) | |
| Yes | 1006 (53.6) | 326 (51.1) | |
| Woken up with feeling of tightness¶ | 0.25 | ||
| No | 1072 (56.6) | 344 (53.9) | |
| Yes | 822 (43.4) | 294 (46.1) | |
| Attack of shortness of breath at rest¶ | 0.69 | ||
| No | 1397 (73.8) | 478 (75.2) | |
| Yes | 496 (26.2) | 158 (24.8) | |
| Shortness of breath during activity¶ | 0.0008 | ||
| No | 961 (50.8) | 280 (44.0) | |
| Yes | 931 (49.2) | 357 (56.0) | |
| Woken up with shortness of breath¶ | 0.02 | ||
| No | 1409 (74.5) | 506 (79.7) | |
| Yes | 482 (25.5) | 129 (20.3) | |
| Woken up by attack of coughing¶ | 0.07 | ||
| No | 1046 (55.3) | 395 (62.0) | |
| Yes | 846 (44.7) | 242 (38.0) | |
| Chronic cough or phlegm | <0.0001 | ||
| No | 1463 (77.5) | 542 (85.3) | |
| Yes | 426 (22.5) | 93 (14.6) | |
| Asthma symptom score¶ | 0.29 | ||
| 0 symptoms | 452 (24.2) | 135 (21.5) | |
| 1–2 symptoms | 750 (40.2) | 276 (43.9) | |
| ≥3 symptoms | 665 (35.6) | 218 (34.6) | |
| Asthma attack¶ | 0.0005 | ||
| No | 1061 (55.5) | 406 (64.0) | |
| Yes | 818 (43.5) | 228 (36.0) | |
| Exacerbation¶ | 0.001 | ||
| No | 1492 (89.8) | 534 (85.2) | |
| Yes | 170 (10.2) | 93 (14.8) | |
| Asthma treatment+ | <0.0001 | ||
| No asthma treatment | 691 (44.0) | 254 (42.2) | |
| Other than daily ICS | 611 (38.9) | 203 (33.7) | |
| Daily ICS | 268 (17.1) | 145 (24.1) | |
| Eczema | 0.0007 | ||
| No | 807 (42.8) | 326 (51.3) | |
| Yes | 1077 (57.2) | 309 (48.7) | |
| Rhinitis | 0.002 | ||
| No | 659 (34.9) | 171 (27.2) | |
| Yes | 1230 (65.1) | 457 (72.8) | |
| Atopy | <0.0001 | ||
| No | 534 (36.3) | 110 (20.3) | |
| Yes | 939 (63.7) | 431 (79.7) | |
| IgE IU·mL−1 | <0.0001 | ||
| <100 | 802 (54.4) | 224 (38.6) | |
| ≥100 | 673 (45.6) | 357 (61.4) | |
| FEV1 % pred | 0.05 | ||
| ≥80% | 1353 (87.0) | 491 (85.0) | |
| <80% | 202 (13.0) | 87 (15.0) | |
| AHR§ | 0.55 | ||
| No | 521 (51.5) | 156 (52.3) | |
| Yes | 490 (48.5) | 142 (47.4) |
Data are presented as n (%), unless otherwise stated. ICS: inhaled corticosteroids; Ig: immunoglobulin; FEV1: forced expiratory volume in 1 s; % pred: % predicted; AHR: airway hyperresponsiveness. #: adjusted for age and sex, except for age and sex, for which unadjusted p-value are given; ¶: in the previous 12 months; +: in the previous 3 months; §: provocative dose causing a 20% fall in FEV1 ≤1 mg methacholine.